A phase <scp>II</scp> study of anlotinib in 45 patients with relapsed small cell lung cancer

Wu, Di; Nie, Jing; Hu, Weiheng; Dai, Lan; Zhang, Jie; Chen, Xiaoling; Ma, Xiao; Tian, Guangming; Han, Jindi; Han, Shiyu; Long, Jieran; Wang, Yang; Zhang, Ziran; Fang, Jian

doi:10.1002/ijc.33161

Cited by 27 publications

(28 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anlotinib has yielded favorable outcomes in lung cancer and was approved for third-line or further-line therapy for both NSCLC [ 117 ] and SCLC [ 118 ] by NMPA. In its phase II trial for patients with relapsed SCLC, a mPFS of 4.1 months was reported [ 119 ]. Similarly, apatinib presented a mPFS of 5.4 months in patients with extensive-stage SCLC after failure of two or more lines of chemotherapy [ 120 ].…”

Section: Vegfr-associated Multi-targeted Tkismentioning

confidence: 99%

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Huang¹,

Jiang²

2020

J Hematol Oncol

315

169

View full text Add to dashboard Cite

Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then block the activation of downstream signaling pathways. Over the past 20 years, multiple robust and well-tolerated TKIs with single or multiple targets including EGFR, ALK, ROS1, HER2, NTRK, VEGFR, RET, MET, MEK, FGFR, PDGFR, and KIT have been developed, contributing to the realization of precision cancer medicine based on individual patient’s genetic alteration features. TKIs have dramatically improved patients’ survival and quality of life, and shifted treatment paradigm of various solid tumors. In this article, we summarized the developing history of TKIs for treatment of solid tumors, aiming to provide up-to-date evidence for clinical decision-making and insight for future studies.

show abstract

Section: Vegfr-associated Multi-targeted Tkismentioning

confidence: 99%

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Huang¹,

Jiang²

2020

J Hematol Oncol

315

169

View full text Add to dashboard Cite

show abstract

“…Moreover, they indicated that limited-stage patients had a longer OS than that of extensive-stage patients. 19 However, Chen et al reported only 2.6 months of PFS in SCLC patients treated with anlotinib in the real-world without reporting data of OS and AEs. 20 Zhang et al reported an advanced SCLC patient treated with anlotinib experienced 11 months duration of response after four lines of treatment.…”

Section: Introductionmentioning

confidence: 99%

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib

Qin

Xin²,

Hou³

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Overall survival (OS) was defined as the duration from the onset of apatinib treatment to death of the patient from any cause. 26 For those who were still receiving apatinib treatment or alive, survival end points were censored at the date of cut-off. The final cut-off date was November 30, 2020.…”

Section: Methodsmentioning

confidence: 99%

Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment

Bai

2021

IJGM

View full text Add to dashboard Cite

Background The aim of the present study was to investigate the influence of kinase insert domain containing receptor (KDR) genetic variation on the efficacy of treatment and safety of patients with chemotherapy-refractory metastatic colorectal cancer (CRC) receiving apatinib. Methods A total of 108 patients with chemotherapy refractory metastatic CRC who were treated with apatinib participated in this study retrospectively. Efficacy of the patients’ treatment was evaluated. Prognosis was carried out and safety profile was documented, respectively. Blood specimens and peripheral blood mononuclear cells (PBMC) of the patients were obtained for the analysis of genetic variation and KDR gene mRNA expression, respectively. The association between genotype status and clinical outcomes was presented. Results Objective response rate (ORR) and disease control rate (DCR) of the 108 patients with metastatic CRC receiving apatinib treatment were 5.6% and 69.4%, respectively. Survival analysis results exhibited that the median progression-free survival (PFS) and overall survival (OS) of the 108 patients with metastatic CRC was 3.6 months (95% confidence interval (CI): 3.03–4.17 months) and 8.9 months (95% CI: 7.57–10.23 months), respectively. Subsequently, the analysis of KDR genetic variation indicated that rs2071559 was of clinical significance. The minor allele frequency of rs2071559 was 0.22 and the genotype status corresponded with Hardy-Weinberg equilibrium ( P =0.949). Prognosis analysis in a dominant inheritance manner through the combination of patients with TC and CC genotype showed that the median PFS of patients with TT genotype and TC/CC genotype was 4.1 and 3.0 months, respectively ( P =0.012). Furthermore, the median OS of patients with the two genotypes was 10.5 and 6.1 months, respectively ( P =0.007). Additionally, multivariate Cox regression analysis of OS showed that TC/CC genotype was an independent factor for OS (Hazard ratio (HR)=0.65, P =0.021). Interestingly, mRNA expression analysis suggested that the mRNA expression of KDR in PBMC differed significantly according to rs2071559 genotype status ( P <0.001). Conclusion Apatinib demonstrated a potentially superior clinical outcome for patients with chemotherapy-refractory metastatic CRC. KDR polymorphism rs2071559 could be used as a potential biomarker for the prognosis evaluation of patients with CRC receiving apatinib therapy.

show abstract

A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer

Cited by 27 publications

References 30 publications

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib

Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment

Contact Info

Product

Resources

About